

## CURRENT REPORT 40/2023

September 14, 2023

### Conclusion of an amendment to global License Agreement with Menarini Group

The Management Board of Ryvu Therapeutics S.A. with its registered office in Kraków ("Issuer", "Company") hereby informs that today the Issuer has concluded an amendment ("Amendment") to the global license agreement ("Agreement") with Berlin-Chemie AG with its registered office in Berlin, Germany, part of the Italian Menarini Group ("Menarini Group"), about which the Issuer informed in the current report no. 4/2017 dated March 28, 2017.

Under the Amendment, Menarini Group will expand development of MEN1703 (SEL24) program by initiating a new Phase II study in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in addition to the continued translational work in other hematologic indications.

The Phase II study, which will explore the activity of MEN1703 in combination with the standard-of-care therapy in DLBCL and as a single agent, is being initiated based on strong preclinical activity of MEN1703 in lymphoma. MEN1703 has completed Phase II studies in relapsed/refractory acute myeloid leukemia (AML), including an expansion cohort in IDH-mutated AML. The studies demonstrated an acceptable safety profile and early signs of single agent activity. Based on these data, development of MEN1703 will continue with focus on DLBCL and potentially other indications. At the same time, according to the information provided by the Menarini Group, AML will be deprioritized given the existing data and competitive landscape.

Pursuant to the Amendment, the Company will assume responsibility from the Menarini Group for conducting the Phase II clinical trial of MEN1703 in relapsed/refractory DLBCL, executing this clinical trial on behalf of the Menarini Group. The Menarini Group will continue to be responsible for all research and development costs, including full reimbursement to the Company for the study execution. The license terms of the Agreement remain unchanged, including the total financial milestones and royalties from the future sales payable to the Company.

*Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.*

**Legal basis:** 17.1 MAR

**Representatives of the Issuer:**

- Paweł Przewięźlikowski – President of the Management Board
- Vatnak Vat-Ho – Member of the Management Board